Hormone replacement therapy should not be prescribed solely to prevent bone-thinning osteoporosis, according to a study in the Women’s Health Initiative.
The study, published in the Journal of the American Medical Association, says the benefit of preventing broken bones is not worth the risks of increased rates of heart disease, breast cancer, strokes and blood clots in the lungs.
The research disputes the policy of the Food and Drug Administration, which permits the use of Prempro, the combined hormone therapy of estrogen and progestin, a form of progesterone, to prevent osteoporosis, the New York Times reported.
FDA officials are scheduled to meet with researchers on Oct. 7 to evaluate the data on osteoporosis. An FDA spokeswoman said it was possible the approved uses of Prempro could change, the Times said.
The medical journal study is based on the same government study that compared 8,102 women who took placebos with 8,506 who took Prempro and found a small increase in the risk of breast cancer, the Times said.
Wyeth, the maker of Prempro, said decisions about hormone use should be made by women and their doctors.
Need Legal Help?
New York City, Long Island, New Jersey, and Florida
Our personal injury attorneys in New York are here to help you when you need it the most.